The feasibility of using concentrates containing factor IX for continuous infusion

Area of Science:

• Hematology
• Biochemistry
• Pharmacology

Background:

• Factor IX (F IX) concentrates are crucial for treating hemophilia B and other bleeding disorders.
• Current treatment protocols often involve intermittent administration, posing challenges for continuous management.
• Investigating novel delivery methods like continuous infusion is essential for improving patient outcomes.

Purpose of the Study:

• To assess the feasibility and stability of continuous infusion of undiluted factor IX (F IX) using minipumps.
• To evaluate the stability of various F IX concentrates under different storage conditions.
• To determine the safety and efficacy of continuous F IX infusion in patients.

Main Methods:

• Stability testing of seven reconstituted F IX products at 4-8°C, 20-23°C, and 37°C.
• Gel electrophoresis analysis of prothrombin complex and F IX concentrates to detect degradation.
• Clinical evaluation of four patients receiving continuous F IX infusion via minipumps post-surgery or for hemorrhage.

Main Results:

• Several F IX concentrates maintained >80% activity for 4 weeks at 4-8°C; one product remained stable for 1 week at 37°C.
• Higher purity F IX products exhibited better stability.
• Continuous F IX infusion in four patients resulted in good hemostatic effect, manageable F IX clearance, and no adverse events.

Conclusions:

• Continuous infusion of undiluted factor IX (F IX) using minipumps is a feasible and effective therapeutic option.
• Pure F IX concentrates offer enhanced stability and safety for prolonged administration.
• This method provides a convenient and potentially improved treatment strategy for bleeding disorders.